+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Bone Cancer Therapy Market - Segmented by Therapy Type, End User, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • PDF Icon


  • 118 Pages
  • March 2018
  • Region: Global
  • Mordor Intelligence
  • ID: 4472806
UP TO OFF until Jun 30th 2023
The global bone cancer therapy market is expected to register a CAGR of 6.0% during the forecast period 2018 to 2023. North America dominates the market due to growing prevalence of bone cancer diseases in the region.

Increasing Incidence of Bone Cancer

According to American Cancer Society (ACS), in 2017, an estimated 3,260 people of all ages (1,820 men and boys and 1,440 women and girls) in the United States were diagnosed with primary bone cancer. Around 400 to 1,000 new cases of osteosarcoma are diagnosed annually in the United States and a similar incidence of osteosarcoma has been reported in Europe. Osteosarcoma accounts for about 3-5% of juvenile cancers. Thus growing incidence of bone cancer couple with growing government initiatives for bone cancer awareness, and aging population globally are anticipated to drive the market of global bone cancer.

Unavailability of Effective Treatment Coupled with Side Effects

Osteosarcoma is a relatively rare cancer, however, about 800 to 900 new cases of osteosarcoma are diagnosed in the United States, annually. About 50% are reported in children and teens. The treatment options for these patients are restricted to few options. In addition, the side effects of available treatment options often are significant and may lead to damage of other organs of body or may lead to other health related severe issues. Additionally, cancer cost is expected to grow in the range of 6% to 9%, annually, during forecast period. Thus, unavailability of effective treatment and side effects of cancers drugs along with rising cost of bone cancer is likely to impede the growth of global bone cancer market.

North America to Dominate the Market

North America dominates the global bone cancer therapy market owing to high prevalence of bone cancer in the region and aging population, coupled with high favorable reimbursement policies in the region. Developing countries are expected to account minimum share owing to less awareness regarding bone cancer among the populations and less availability of effective treatment option for bone cancer in the region. However, penetration of key players in the region coupled with aging populations are anticipated to drive the market growth of bone cancer in the emerging countries of Asia Pacific.

Key Developments in the Market
  • September 2016: Dr Reddy's Laboratories (DRL) expanded strategic collaboration with Amgen to market and distribute Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India.


Reasons to Purchase this Report
  • Current and future global bone cancer therapy market outlook in the developed and emerging markets

  • Analyzing various perspectives of the market with the help of Porter’s five forces analysis

  • The segment that is expected to dominate the market

  • Regions that are expected to witness fastest growth during the forecast period

  • Identify the latest developments, market shares and strategies employed by the major market players

  • 3 months analyst support along with the Market Estimate sheet (in excel)

Customization of the Report

This report can be customized to meet your requirements.

This product will be delivered within 2 business days.

Table of Contents

1. Introduction
1.1 Market Definition
2. Research Methodology3. Executive Summary4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidence of Bone Cancer
6.1.2 Growing Government Initiatives for Bone Cancer Awareness
6.1.3 Aging Population
6.2 Market Restraints
6.2.1 Unavailability of Effective Treatment Coupled with Side Effects
6.2.2 High Cost of Cancer Therapies
6.3 Market Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Treatment Type
7.1.1 Chemotherapy Doxorubicin Cisplatin Carboplatin Etoposide Ifosfamide Cyclophosphamide Methotrexate Vincristine
7.1.2 Targeted Therapy Denosumab Imatinib
7.1.3 Radiation Therapy
7.1.4 Surgery
7.2 By End User
7.2.1 Hospitals
7.2.2 Specialty Clinics
7.2.3 Cancer and Radiation Therapy Centers
7.3 By Geography
7.3.1 North America United States Canada Mexico
7.3.2 Europe France Germany United Kingdom Italy Spain Rest of Europe
7.3.3 Asia-Pacific China Japan India Australia & New Zealand South Korea Rest of Asia-Pacific
7.3.4 Middle East & Africa GCC South Africa Rest of the Middle East & Africa
7.3.5 South America Brazil Argentina Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Actavis plc
9.2 Amgen
9.3 Bayer AG
9.4 F. Hoffmann-La Roche Ltd
9.5 IDM Pharma, SA
9.6 Merck & Co., Inc.
9.7 Novartis AG
9.8 Pfizer Inc.
9.9 Others
10. Future of the Market

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen

  • Astrazeneca

  • Bristol-Meyrs Squibb Company

  • Bayer Ag

  • F. Hoffmann-La Roche Ltd.

  • Glaxosmithkline Plc

  • Johnson & Johnson

  • Merck & Co. Inc.

  • Novartis Ag

  • Pfizer Inc.